ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2022
Improved Glycemic Control Observed in Children with Type 1 Diabetes Following the Introduction of Smart Insulin Pens: A Real-World Study.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies - Insulin Delivery.Hormone research in paediatrics · 2024Guideline
- Impact of User Responses to Smart MDI Notifications: Insights From a Longitudinal Real-World Study of 2604 Smart MDI System Users.Diabetes, obesity & metabolism · 2026Article
- Effectiveness of the Stage 4 Smart Insulin Pen DIA:CONN P8 for Glycemic Control in a Real-World Setting.Diabetes & metabolism journal · 2026Article
- Contributions of intermittently scanned continuous glucose monitoring frequency and bolus insulin dosing on time in range: Analysis of data from CGM and connected insulin pens.Diabetes, obesity & metabolism · 2025Article
- Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Glycaemic control after connected insulin pen initiation in people living with diabetes: Results from a real-world setting.Diabetes, obesity & metabolism · 2025Observational
- Article
- Pediatrics 4.0: the Transformative Impacts of the Latest Industrial Revolution on Pediatrics.Health care analysis : HCA : journal of health philosophy and policy · 2025Article
- Current Perspective on the Potential Benefits of Smart Insulin Pens on Glycemic Control in Patients With Diabetes: Spanish Delphi Consensus.Journal of diabetes science and technology · 2025Article
- Understanding Suboptimal Insulin Use in Type 1 and Type 2 Diabetes: A Cross-Sectional Survey of People with Diabetes.Patient preference and adherence · 2025Article
- Criteria for Personalised Choice of a Continuous Glucose Monitoring System: An Expert Opinion.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Use of diabetes technology in children.Diabetologia · 2024Review
- Opportunities for digitally-enabled personalization and decision support for pediatric growth hormone therapy.Frontiers in endocrinology · 2024Review
- Connected Insulin Pens and Caps: An Expert's Recommendation from the Area of Diabetes of the Spanish Endocrinology and Nutrition Society (SEEN).Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control.Diabetes & metabolism journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMany challenges are associated with optimizing glycemic control in pediatric patients with type 1 diabetes (T1D); combining data from smart insulin pens and continuous glucose monitoring (CGM) could mitigate some of these obstacles.
methodsThis one-arm, prospective, observational study investigated the effects of introducing a smart pen on glycemic control in pediatric patients with T1D who were using CGM. Children and adolescents with T1D who had been prescribed a smart pen for basal and/or bolus insulin injections were enrolled from three clinics in Sweden. Outcomes compared between baseline and follow-up (≥ 12 months) included: mean numbers of daily (over 24 h) and nocturnal hypoglycemic or hyperglycemic events; time above range (TAR; > 180 mg/dL); time below range (TBR; level 1: 54 to < 70 mg/dL; level 2: < 54 mg/dL); time in range (TIR; 70-180 mg/dL); and missed bolus-dose (MBD) meals.
resultsOverall, 39 patients were included. Mean numbers of daily hypoglycemic events (- 31.4%; p = 0.00035) and nocturnal hypoglycemic events (- 24.4%; p = 0.043) were significantly reduced from baseline to follow-up. Mean daily TBR level 2 was reduced from 2.82% at baseline to 2.18% at follow-up (- 0.64 percentage points; p = 0.025). There were no statistically significant changes in number of daily hyperglycemic events, MBD meals, TIR, TAR, or TBR level 1.
conclusionsIntroducing smart insulin pens was associated with a reduced number of hypoglycemic events and decreases in TBR level 2, demonstrating a potential benefit for glycemic control in pediatric patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.